Securian Asset Management Inc. Sells 36,771 Shares of Abbott Laboratories $ABT

Securian Asset Management Inc. decreased its holdings in Abbott Laboratories (NYSE:ABT) by 43.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 47,283 shares of the healthcare product maker’s stock after selling 36,771 shares during the period. Securian Asset Management Inc.’s holdings in Abbott Laboratories were worth $5,924,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Harbor Capital Advisors Inc. bought a new stake in Abbott Laboratories during the 4th quarter worth $27,000. Cloud Capital Management LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $29,000. Guerra Advisors Inc acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $31,000. Bridge Generations Wealth Management LLC acquired a new position in shares of Abbott Laboratories in the 3rd quarter valued at about $33,000. Finally, Copia Wealth Management acquired a new position in Abbott Laboratories during the 3rd quarter worth approximately $38,000. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Trading Down 0.1%

NYSE ABT opened at $84.24 on Monday. The stock’s 50-day simple moving average is $102.69 and its two-hundred day simple moving average is $115.09. Abbott Laboratories has a twelve month low of $84.08 and a twelve month high of $139.06. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $146.72 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 1.41 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the business posted $1.09 earnings per share. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Insider Activity

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Eric Shroff sold 709 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the sale, the senior vice president directly owned 39,164 shares in the company, valued at $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 3,055 shares of company stock valued at $353,097. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott’s Medical Devices segment delivered 8.5% Q1 growth, with electrophysiology, rhythm management, and heart failure products driving gains. That reinforces the company’s long-term growth story and suggests its device portfolio remains a key catalyst for ABT. Abbott’s Medical Device Strategy Supports Long-Term Growth Outlook
• Positive Sentiment: Wall Street analysts remain bullish on Abbott Laboratories despite its recent underperformance versus the broader market, which can help cushion sentiment around the stock. Abbott Laboratories Stock: Analyst Estimates & Ratings
• Positive Sentiment: Wells Fargo reaffirmed its Buy rating on ABT, adding to the view that analysts still see upside potential despite near-term weakness. Wells Fargo Reaffirms Their Buy Rating on Abbott Laboratories (ABT)
• Neutral Sentiment: Erste Group Bank slightly lowered its FY2026 EPS estimate for Abbott to $5.47 from $5.48, which is only a minor change and close to consensus, so the impact looks limited. Abbott Laboratories news item referencing Erste Group Bank estimate reduction
• Negative Sentiment: ABT has underperformed over the past year, and recent share-price weakness has kept investors focused on whether the stock is now cheap rather than on a strong near-term rebound. Is Abbott Laboratories (ABT) Now Offering Value After Recent Share Price Weakness?

Analyst Ratings Changes

A number of research firms recently weighed in on ABT. Argus dropped their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Benchmark reduced their target price on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Sanford C. Bernstein reduced their price objective on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a report on Friday, April 17th. TD Cowen reduced their price objective on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a report on Friday, April 17th. Finally, Piper Sandler dropped their target price on Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $119.43.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.